Paul Huggan
@midlandsid.bsky.social
Sepsis researcher, specialist, educator and ID enthusiast, based in the Waikato, Aotearoa New Zealand.
Also very low mortality (<5%) in the confirmed bacterial infection group. Crude mortality in our red flag sepsis cohort is around 20%.
April 18, 2025 at 3:06 AM
Also very low mortality (<5%) in the confirmed bacterial infection group. Crude mortality in our red flag sepsis cohort is around 20%.
In a study of 600 patients with sepsis, mortality amongst patients with suspected bacterial sepsis was only 4.5%, meaning they probably didn’t have sepsis. Will need to read the full text on this one.
April 17, 2025 at 11:12 AM
In a study of 600 patients with sepsis, mortality amongst patients with suspected bacterial sepsis was only 4.5%, meaning they probably didn’t have sepsis. Will need to read the full text on this one.
Pretty unfair to criticize broad spectrum antibiotic use in retrospect- you go broad if you don’t have investigations/micro. US problem seems to be defaulting to pseudo and MRSA cover up front. Similar rates of resistance here but we recommend fluclox/gent’ for undifferentiated sepsis.
April 16, 2025 at 9:21 PM
Pretty unfair to criticize broad spectrum antibiotic use in retrospect- you go broad if you don’t have investigations/micro. US problem seems to be defaulting to pseudo and MRSA cover up front. Similar rates of resistance here but we recommend fluclox/gent’ for undifferentiated sepsis.
Reposted by Paul Huggan
Dr Joshua Davis presents data on Cefazolin vs (Flu)cloxacillin for MSSA.
1. Cefazolin is non-inferior.
2. Less AKI with Cefazolin.
#ESCMIDGlobal
1. Cefazolin is non-inferior.
2. Less AKI with Cefazolin.
#ESCMIDGlobal
April 12, 2025 at 3:13 PM
Dr Joshua Davis presents data on Cefazolin vs (Flu)cloxacillin for MSSA.
1. Cefazolin is non-inferior.
2. Less AKI with Cefazolin.
#ESCMIDGlobal
1. Cefazolin is non-inferior.
2. Less AKI with Cefazolin.
#ESCMIDGlobal
Novel outbreak of (x) related to French Horn mouthpiece sharing at Infectious Disease conference. Vienna, 2025.
April 16, 2025 at 4:51 AM
Novel outbreak of (x) related to French Horn mouthpiece sharing at Infectious Disease conference. Vienna, 2025.
13%–57% of invasive S.aureus isolates. Labs need to be confident with manual testing. pmc.ncbi.nlm.nih.gov/articles/PMC...
A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus
There is clinical uncertainty over the optimal treatment for penicillin-susceptible Staphylococcus aureus (PSSA) infections. Furthermore, there is concern that phenotypic penicillin susceptibility tes...
pmc.ncbi.nlm.nih.gov
April 13, 2025 at 4:05 AM
13%–57% of invasive S.aureus isolates. Labs need to be confident with manual testing. pmc.ncbi.nlm.nih.gov/articles/PMC...
Reposted by Paul Huggan
I am thankful to people like you who lay it on the line when things are wrong. This whole administration is beyond mediocre--it is dreadful.
March 26, 2025 at 3:47 AM
I am thankful to people like you who lay it on the line when things are wrong. This whole administration is beyond mediocre--it is dreadful.